Total Payments
$85,206
2024 Payments
$2,055
Companies
11
Transactions
93
Medicare Patients
660
Medicare Billing
$109,840
Payment Breakdown by Category
Consulting$61,657 (72.4%)
Travel$21,808 (25.6%)
Food & Beverage$1,629 (1.9%)
Research$100.42 (0.1%)
Education$12.45 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,657 | 21 | 72.4% |
| Travel and Lodging | $21,808 | 31 | 25.6% |
| Food and Beverage | $1,629 | 38 | 1.9% |
| Unspecified | $100.42 | 2 | 0.1% |
| Education | $12.45 | 1 | 0.0% |
Payments by Type
General
$85,106
91 transactions
Research
$100.42
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $34,494 | 53 | $0 (2020) |
| F. Hoffmann-La Roche AG | $15,080 | 4 | $0 (2018) |
| Genentech USA, Inc. | $9,287 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $9,028 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $8,202 | 16 | $0 (2018) |
| Puma Biotechnology, Inc. | $3,900 | 2 | $0 (2023) |
| Amgen Inc. | $1,947 | 1 | $0 (2021) |
| Daiichi Sankyo Inc. | $1,875 | 1 | $0 (2023) |
| AstraZeneca UK Limited | $1,370 | 1 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,055 | 2 | AstraZeneca UK Limited ($1,370) |
| 2023 | $5,775 | 3 | Puma Biotechnology, Inc. ($3,900) |
| 2022 | $1,713 | 1 | AstraZeneca Pharmaceuticals LP ($1,713) |
| 2021 | $7,427 | 4 | AstraZeneca Pharmaceuticals LP ($5,480) |
| 2020 | $6,128 | 3 | AbbVie Inc. ($6,116) |
| 2019 | $1,247 | 7 | AstraZeneca Pharmaceuticals LP ($1,150) |
| 2018 | $36,353 | 35 | AbbVie, Inc. ($16,967) |
| 2017 | $24,509 | 38 | AbbVie, Inc. ($11,412) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2024 | AstraZeneca UK Limited | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 04/26/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| 03/09/2023 | Puma Biotechnology, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 01/05/2023 | Puma Biotechnology, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 05/02/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 08/10/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 06/30/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| 06/09/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 03/04/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/16/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 01/21/2020 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $6,050.00 | General |
| 01/21/2020 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $66.00 | General |
| 10/01/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $686.29 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $193.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $189.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $68.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/28/2019 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $85.23 | General |
| Category: BioOncology | ||||||
| 02/06/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: None | ||||||
| 12/19/2018 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 11/23/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 10/11/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Travel and Lodging | In-kind items and services | $7,563.76 | General |
| Category: BioOncology | ||||||
| 10/11/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| Category: BioOncology | ||||||
| 10/11/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Travel and Lodging | In-kind items and services | $558.39 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SCRX001-004 | AbbVie, Inc. | $55.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 192 | 293 | $100,378 | $28,659 |
| 2022 | 5 | 153 | 252 | $71,070 | $24,549 |
| 2021 | 4 | 174 | 325 | $92,186 | $34,515 |
| 2020 | 4 | 141 | 252 | $74,080 | $22,117 |
Total Patients
660
Total Services
1,122
Medicare Billing
$109,840
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 101 | $39,943 | $11,641 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 36 | $13,867 | $3,954 | 28.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $10,398 | $2,618 | 25.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 36 | $7,508 | $2,452 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 27 | $7,928 | $2,232 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 21 | 25 | $7,526 | $2,003 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $6,253 | $1,474 | 23.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 13 | 13 | $4,147 | $1,268 | 30.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 15 | 24 | $2,808 | $1,016 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 68 | $21,886 | $7,982 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 46 | $14,805 | $5,028 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 40 | $9,530 | $3,185 | 33.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 34 | $8,101 | $2,569 | 31.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 40 | $6,831 | $2,472 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $5,531 | $1,889 | 34.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $4,386 | $1,425 | 32.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 113 | $36,369 | $14,148 | 38.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 68 | $21,886 | $8,413 | 38.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 66 | $15,725 | $5,589 | 35.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 32 | $7,624 | $2,772 | 36.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 32 | $5,465 | $1,997 | 36.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 14 | 14 | $5,117 | $1,596 | 31.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 45 | 101 | $32,507 | $9,271 | 28.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 49 | $15,771 | $4,837 | 30.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 28 | 44 | $10,483 | $2,940 | 28.0% |
About Christine Hann, M.D., PH.D
Christine Hann, M.D., PH.D is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336295021.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christine Hann, M.D., PH.D has received a total of $85,206 in payments from pharmaceutical and medical device companies, with $2,055 received in 2024. These payments were reported across 93 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($61,657).
As a Medicare-enrolled provider, Hann has provided services to 660 Medicare beneficiaries, totaling 1,122 services with total Medicare billing of $109,840. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 01/26/2007
- Last Updated 02/07/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336295021
Products in Payments
- TECENTRIQ (Biological) $15,181
- Non-Covered Product (Drug) $9,111
- IMFINZI (Biological) $8,563
- OPDIVO (Biological) $8,065
- IMFINZI (Drug) $1,150
- Avastin (Biological) $85.23
- XPOVIO (Drug) $12.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816